Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non‐smokers
- 1 May 1992
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 22 (5) , 301-306
- https://doi.org/10.1111/j.1365-2362.1992.tb01466.x
Abstract
To evaluate indicators of inflammatory changes in the airways of young smokers we have measured the levels of several eicosanoids in bronchoalveolar lavage (BAL) fluid of 18 female smokers (age 33 ±2 years) and 9 female non‐smokers (age 29 ± 2 years) who were hospitalized for treatment not related to any pulmonary disease. In each BAL specimen the following eicosanoids were determined by radioimmunoassay: prostaglandin (PG) E2; PGF2x; 9α, 1 lβ‐PGF2, a metabolite of PGD2; 6‐keto PGF1x, a metabolite of prostacyclin; thromboxane (Tx) B2, a metabolite of TxA2; the 5‐lipoxygenase products 5‐hydroxy‐eicosa‐tetraenoic acid (HETE), leukotriene (LT) B4 and LTC4; the 12‐lipoxygenase product 12‐HETE; and the 15‐lipoxygenase product 15‐HETE. The concentrations of the cyclooxygenase products (pg ml‐1) in the BAL fluid of the non‐smokers were: PGE2 15.4±1.9, PGF2x, 7.6±1.0, 9α,11β‐PGF2 8.7±1.8, TxB2 8.8 ± 1.3, and 6‐keto PGF1α only 1.5±0.8. The concentration of the lipoxygenase products were: 15‐HETE 781 ± 200,12‐HETE 193 ± 33,5‐HETE 14.0 ± 3.1, LTC49.5±3.1, LTB46.2± 1.4. BAL fluid from smokers contained two‐ to three‐fold higher levels of TxB2 and PGF2α (P < 0.05). The levels of TxB2 and PGF2α were positively correlated to the number of package years (rs= 0.55 and rs= 0.65, P<0.02). The concentrations of 5‐, 12‐ and 15‐HETE tended to be higher in BAL fluid from smokers, but this was not significant. We conclude that in BAL fluid from females who denied pulmonary symptoms, the concentration of 12‐ and 15‐lipoxygenase products is 15 — 100‐fold higher than that of 5‐lipoxygenase or cyclooxygenase products. In these subjects smoking is associated with higher concentrations of bronchoconstrictive cyclooxygenase products and a tendency towards higher levels of 5‐, 12‐ and 15‐HETE, probably reflecting inflammatory changes in the airways. Therefore, these results indicate that smoking induces formation of the metabolites that may play a role in the development of chronic airways obstruction especially when inflammatory changes become more pronounced after greater exposure to tobacco smoke.Keywords
This publication has 22 references indexed in Scilit:
- Expression of the CD11/CD18 Cell Surface Adhesion Glycoprotein Family on Alveolar Macrophages in Smokers and NonsmokersChest, 1991
- Spectrum of Prostanoid Release after Bronchoalveolar Allergen Challenge in Atopic Asthmatics and in Control Groups: An Alteration in the Ratio of Bronchoconstrictive to Bronchoprotective MediatorsAmerican Review of Respiratory Disease, 1989
- 15-Hydroxy-eicosatetraenoic acid (15-Hete) inhibits carragheenan-induced experimental arthritis and reduces synovial fluid leukotriene B4 (LTB4)Prostaglandins, 1989
- Measurement of human small airway smooth muscle function in vitroJournal of Pharmacological Methods, 1988
- Ability of 15-hydroxyeicosatrienoic acid (15-OH-20:3) to modulate macrophage arachidonic acid metabolismBiochemical and Biophysical Research Communications, 1988
- Decreased leukotriene B4 synthesis in smokers' alveolar macrophages in vitro.Journal of Clinical Investigation, 1986
- Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndromeJournal of Clinical Immunology, 1984
- The Bronchoconstrictor Effect of Inhaled Prostaglandin D2 in Normal and Asthmatic MenNew England Journal of Medicine, 1984
- Determination of the formation of thromboxane B2 (TxB2), 12L-hydroxy-5,8,10 heptadecatrienoic acid (HETE) AND 12L-hydroxy-5,8,10,14 eicosatrienoic acid (HETE) from arachidonic acid and of the TxB2:HHT, TxB2:HETE and (TxB2+HHT):HETE ratio in human platelets. possible use in diagnostic pursesProstaglandins and Medicine, 1980
- Metabolism of arachidonic acid in ionophore-stimulated neutrophils. Esterification of a hydroxylated metabolite into phospholipids.Journal of Clinical Investigation, 1979